Royalty Pharma PLC

Common Name

Royalty Pharma

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

N/A

Ticker

RPRX

Exchange

NASDAQ/NGS

Website

www.royaltypharma.com

Description

Royalty Pharma plc is a unique player in the pharmaceutical sector, specializing in the acquisition of biopharmaceutical royalties. Its primary function is to provide critical funding to research and ... Show more

Financial Statements of Royalty Pharma

Below are the financial statements of Royalty Pharma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Income Statement (as reported) Balance Sheet (as reported)

All figures in millions of USD	2024	2023
Current assets	—	—
Cash and cash equivalents	929.03^a	477.01^a
Financial royalty assets	783.77^a	738.44^a
Available for sale debt securities	58.2^a	18.3^a
Other royalty income receivable	26.96^a	22.41^a
Other current assets	4.19^a	18.04^a
Total current assets	1,802.14^a	1,274.19^a
Assets	—	—
Financial royalty assets, net	15,127.16^a	14,088.66^a
Equity securities	186.96^a	199.49^a
Available for sale debt securities	693.5^a	437.1^a
Equity method investments	379.42^a	375.89^a
Other assets	33.53^a	6.52^a
Total assets	18,222.72^a	16,381.85^a
Current liabilities	—	—
Distributions payable to legacy non-controlling interests	75.81^a	83.16^a
Accounts payable and accrued expenses	13.37^a	15.17^a
Interest payable	98.06^a	51.68^a
Current portion of long-term debt	997.77^a	0^a
Other current liabilities	68.6^a	11.38^a
Total current liabilities	1,253.62^a	161.38^a
Liabilities and shareholders’ equity	—	—
Long-term debt	6,614.65^a	6,135.29^a
Other liabilities	12.08^a	0.9^a
Total liabilities	7,880.35^a	6,297.56^a
Shareholders’ equity	—	—
Class A ordinary shares	0.05^a	0.05^a
Class B ordinary shares	0^a	0^a
Class R redeemable shares	0.06^a	0.06^a
Deferred shares	0^a	0^a
Additional paid-in capital	4,103.48^a	4,011.44^a
Retained earnings	2,845.65^a	2,517.58^a
Non-controlling interests	3,395.79^a	3,557.79^a
Treasury interests	-2.66^a	-2.63^a
Total shareholders’ equity	10,342.37^a	10,084.29^a
Total liabilities and shareholders’ equity	18,222.72^a	16,381.85^a

Verified Sources Behind Royalty Pharma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Royalty Pharma’s data sources below and access millions more through our Disclosure Search.

a. Royalty Pharma's 10-K 2024

Trace every data point back to Royalty Pharma’s disclosures

Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

At Tracenable, we're exploring the launch of real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Royalty Pharma PLC

Financial Statements of Royalty Pharma

Verified Sources Behind Royalty Pharma’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

Halozyme Therapeutics Inc

Bio-Techne Corp

Incyte Corp

Immunovant Inc

Ultragenyx Pharmaceutical Inc

Cytokinetics Inc